Ekso Bionics to Report First Quarter 2021 Financial Results on April 29, 2021
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q1 2021 after market close on April 29, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) will release its financial and business results for Q1 2021 after market close on April 29, 2021. A conference call will follow at 1:30 p.m. PT to discuss these results and recent developments. Investors can access the call via phone or through a live webcast on the company’s website. A replay will be available for two weeks post-call. Founded in 2005, Ekso Bionics specializes in exoskeleton solutions that enhance strength and mobility for medical and industrial applications.
Positive
- Upcoming Q1 2021 financial results release on April 29, 2021.
- Management will address recent business developments in the conference call.
Negative
- None.
Details
News Market Reaction – EKSO
The recorded move for EKSO in the trading session of this news was -1.61%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RICHMOND, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2021 after the close of trading on Thursday, April 29, 2021. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments.
A live webcast of the event will be available in the “Investors” section of the Company’s website at www.eksobionics.com, or by clicking here. Investors interested in listening to the conference call may do so by dialing 877-407-3036 for domestic callers or 201-378-4919 for international callers.
A replay of the call will be available for two weeks by dialing 877-660-6853 for domestic callers or 201-612-7415 for international callers and using Conference ID: 13718303. The webcast will also be available on the Company’s website for one month following the completion of the call.
About Ekso Bionics®
Ekso Bionics® is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the Company continues to build upon its industry-leading expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The Company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol “EKSO.” For more information, visit: www.eksobionics.com or follow @EksoBionics on Twitter.
Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.